Medtronic Gears Up For FDA Panel With Mixed Results From AF Ablation Trial
This article was originally published in The Gray Sheet
Executive SummaryMedtronic could face more questions than expected at an FDA advisory panel meeting later this month for the firm’s Phased RF Ablation System for atrial fibrillation due to mixed pivotal trial results released last week.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.